Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
LGND Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
25.30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
8.40%
LGND Stock Analysis
LGND
PE Ratio:
31.5
LGND
PEG Ratio:
1
LGND
Forward EPS Growth (12 month):
30.50%
LGND
PS Ratio:
17.1
LGND
PSG Ratio:
0.5
LGND
Forward Revenue Growth (12 month):
32.70%
LGND Articles
No data was found